Loading viewer...
investor_presentation
Format: PDF investor_presentation
AMAG Pharmaceuticals presented Q2 2018 financial results and strategic updates on its pharmaceutical portfolio including Feraheme, Makena, Intrarosa, and Vyleesi (bremelanotide). The company reported strong revenue growth to $146.3M and announced the sale of its CBR business unit to strengthen its balance sheet. Key developments included FDA acceptance of the Vyleesi NDA with a PDUFA date of March 23, 2019.
presentation
investor_presentation
Cogent
investor_presentation
Genmab